



Qdata® Myelodysplastic Syndrome is an exclusive dataset providing a longitudinal view of diagnosis, risk classification, treatment patterns, and real-world outcomes in real-world clinical practice.

Verana Health® powers oncology research with high-quality real-world data sourced from curated electronic health records and linked data sources at leading cancer centers across the US. Built specifically for cancer research, Verana Health's oncology datasets and analytics deliver clinically rich insights across tumor types and lines of therapy, supporting evidence generation at every stage of the drug development and commercialization lifecycle.

Abstracted Data


ABSTRACTED	ACCESSIBLE	ABSTRACTED + ACCESSIBLE
6,080	16,740+	22,820+

Potential patients as of Q2 2026

Note: Abstracted data is available for immediate delivery. Accessible data requires additional curation.

Clinician-led and AI-enabled oncology data platform

Verana Health securely ingests, links, and curates raw oncology care data from point-of-care clinical encounters. Purpose-built, fit-for-purpose data is designed to support rigorous research and confident decision-making across the oncology lifecycle.



Abstracted Data Summary:

DATA SET QUALITY

2.8 yrs	Average length of follow-up	94%	Patients with race data
20.6	Performance statuses on avg. per patient	88%	Patients with ethnicity data
81%	patients with performance status	33%	Patients with outcome data
13%	of MDS patients transformed to AML		

RISK GROUPS

Low	1,733
Intermediate	1,595
High	719
Very High	248

TREATMENT HIGHLIGHTS

Venetoclax	306
Hypomethylating Agents	2,588
1,615 Relapse/Refractory	Total 6,080

About Verana Health

Verana Health, Inc.® is a digital health company revolutionizing patient care and clinical research by utilizing physician expertise and artificial intelligence to unlock the true potential of real-world data. With exclusive access to the world's largest patient data sources in oncology, ophthalmology, neurology, and urology. Verana Health is powering real-world evidence generation. Clinicians utilize these insights to improve the quality of care and quality of life for patients, and life sciences companies rely on the insights to accelerate the development of new therapies. For more information, visit www.veranahealth.com.